These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 35028304)

  • 21. Repurposing existing drugs: identification of SARS-CoV-2 3C-like protease inhibitors.
    Chiou WC; Hsu MS; Chen YT; Yang JM; Tsay YG; Huang HC; Huang C
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):147-153. PubMed ID: 33430659
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Study of Drug Repurposing to Identify SARS-CoV-2 Main Protease (3CLpro) Inhibitors.
    Jo S; Signorile L; Kim S; Kim MS; Huertas O; Insa R; Reig N; Shin DH
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742913
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
    Froggatt HM; Heaton BE; Heaton NS
    J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacoinformatics and molecular dynamics simulation studies reveal potential covalent and FDA-approved inhibitors of SARS-CoV-2 main protease 3CL
    Alamri MA; Tahir Ul Qamar M; Mirza MU; Bhadane R; Alqahtani SM; Muneer I; Froeyen M; Salo-Ahen OMH
    J Biomol Struct Dyn; 2021 Aug; 39(13):4936-4948. PubMed ID: 32579061
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of a novel inhibitor of SARS-CoV-2 3CL-PRO through virtual screening and molecular dynamics simulation.
    Bepari AK; Reza HM
    PeerJ; 2021; 9():e11261. PubMed ID: 33954055
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
    Kumar Y; Singh H; Patel CN
    J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Establishing an Analogue Based In Silico Pipeline in the Pursuit of Novel Inhibitory Scaffolds against the SARS Coronavirus 2 Papain-Like Protease.
    Hajbabaie R; Harper MT; Rahman T
    Molecules; 2021 Feb; 26(4):. PubMed ID: 33672721
    [TBL] [Abstract][Full Text] [Related]  

  • 28.
    Gurung AB
    Gene Rep; 2020 Dec; 21():100860. PubMed ID: 32875166
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of highly effective inhibitors against SARS-CoV-2 main protease: From virtual screening to in vitro study.
    Wang H; Wen J; Yang Y; Liu H; Wang S; Ding X; Zhou C; Zhang X
    Front Pharmacol; 2022; 13():1036208. PubMed ID: 36467060
    [No Abstract]   [Full Text] [Related]  

  • 30. Targeting SARS-CoV-2 Main Protease: A Computational Drug Repurposing Study.
    Baby K; Maity S; Mehta CH; Suresh A; Nayak UY; Nayak Y
    Arch Med Res; 2021 Jan; 52(1):38-47. PubMed ID: 32962867
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prioritisation of Compounds for 3CL
    Jukič M; Škrlj B; Tomšič G; Pleško S; Podlipnik Č; Bren U
    Molecules; 2021 May; 26(10):. PubMed ID: 34070140
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of potential SARS-CoV 3CL protease inhibitors from approved antiviral drugs using: virtual screening, molecular docking, pharmacophore mapping evaluation and dynamics simulation.
    Daoud I; Mesli F; Melkemi N; Ghalem S; Salah T
    J Biomol Struct Dyn; 2022; 40(23):12574-12591. PubMed ID: 34541995
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug repurposing against SARS-CoV-2 using E-pharmacophore based virtual screening, molecular docking and molecular dynamics with main protease as the target.
    Arun KG; Sharanya CS; Abhithaj J; Francis D; Sadasivan C
    J Biomol Struct Dyn; 2021 Aug; 39(13):4647-4658. PubMed ID: 32571168
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Repurposed Drugs Suramin and Quinacrine Cooperatively Inhibit SARS-CoV-2 3CL
    Eberle RJ; Olivier DS; Amaral MS; Gering I; Willbold D; Arni RK; Coronado MA
    Viruses; 2021 May; 13(5):. PubMed ID: 34068686
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening.
    Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T
    Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evolving geographic diversity in SARS-CoV2 and in silico analysis of replicating enzyme 3CL
    Chitranshi N; Gupta VK; Rajput R; Godinez A; Pushpitha K; Shen T; Mirzaei M; You Y; Basavarajappa D; Gupta V; Graham SL
    J Transl Med; 2020 Jul; 18(1):278. PubMed ID: 32646487
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Virtual high throughput screening: Potential inhibitors for SARS-CoV-2 PL
    Jade D; Ayyamperumal S; Tallapaneni V; Joghee Nanjan CM; Barge S; Mohan S; Nanjan MJ
    Eur J Pharmacol; 2021 Jun; 901():174082. PubMed ID: 33823185
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparative analysis of SARS-CoV-2 antivirals characterizes 3CL
    de Vries M; Mohamed AS; Prescott RA; Valero-Jimenez AM; Desvignes L; O'Connor R; Steppan C; Devlin JC; Ivanova E; Herrera A; Schinlever A; Loose P; Ruggles K; Koralov SB; Anderson AS; Binder J; Dittmann M
    J Virol; 2021 Mar; 95(7):. PubMed ID: 33622961
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ensemble Docking Coupled to Linear Interaction Energy Calculations for Identification of Coronavirus Main Protease (3CL
    Jukič M; Janežič D; Bren U
    Molecules; 2020 Dec; 25(24):. PubMed ID: 33316996
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drugs Repurposing Using QSAR, Docking and Molecular Dynamics for Possible Inhibitors of the SARS-CoV-2 M
    Tejera E; Munteanu CR; López-Cortés A; Cabrera-Andrade A; Pérez-Castillo Y
    Molecules; 2020 Nov; 25(21):. PubMed ID: 33172092
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.